| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| F García-Río, J M Pino, J J Díez, A Ruíz, C Villasante, J Villamo. Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion. American journal of respiratory and critical care medicine. vol 164. issue 5. 2002-07-02. PMID:11549545. |
we conclude that the increased lung distensibility with normal diffusion capacity demonstrated in patients with active acromegaly, which was partly reversible after suppression of gh hypersecretion, suggests that lung growth in acromegaly may result from an increase in alveolar size. |
2002-07-02 |
2023-08-12 |
human |
| P B Colligan, H M Brown-Borg, J Duan, B H Ren, J Re. Cardiac contractile function is enhanced in isolated ventricular myocytes from growth hormone transgenic mice. The Journal of endocrinology. vol 173. issue 2. 2002-06-25. PMID:12010633. |
transgenic mice with gh over-expression serve as useful models for acromegaly and exhibit impaired cardiac functions using echocardiography, similar to those of human acromegaly. |
2002-06-25 |
2023-08-12 |
mouse |
| M Bolanowski, D Jedrzejuk, A Milewicz, A Arkowsk. Quantitative ultrasound of the heel and some parameters of bone turnover in patients with acromegaly. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. vol 13. issue 4. 2002-06-20. PMID:12030545. |
acromegaly caused by growth hormone (gh) hypersecretion is characterized by enhanced skeletal growth and soft tissue enlargement. |
2002-06-20 |
2023-08-12 |
Not clear |
| M Bolanowski, D Jedrzejuk, A Milewicz, A Arkowsk. Quantitative ultrasound of the heel and some parameters of bone turnover in patients with acromegaly. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. vol 13. issue 4. 2002-06-20. PMID:12030545. |
however, in some patients with acromegaly, secondary osteoporosis is observed, despite the strong anabolic effect of gh and igf-1 in bones. |
2002-06-20 |
2023-08-12 |
Not clear |
| Patric J D Delhanty, Dieter Mesotten, Fiona McDougall, Robert C Baxte. Growth hormone rapidly induces resistin gene expression in white adipose tissue of spontaneous dwarf (SDR) rats. Endocrinology. vol 143. issue 6. 2002-06-18. PMID:12021211. |
growth hormone is an important regulator of metabolism; both acromegaly and gh therapy in gh-deficiency are associated with a tendency towards insulin-resistance and loss of adiposity. |
2002-06-18 |
2023-08-12 |
human |
| A Colao, M Dorato, M Pulcrano, F W Rossi, R S Auriemma, G Lombardi, S Lastori. [Somatostatin analogs in the clinical management of pituitary neoplasms]. Minerva endocrinologica. vol 26. issue 3. 2002-05-20. PMID:11753242. |
they were first used to treat acromegaly in the mid 1980s and numerous studies have shown a reduction in gh concentration in over 90% of acromegalic patients. |
2002-05-20 |
2023-08-12 |
Not clear |
| C Parkinson, W M Drake, G Wieringa, A P Yates, G M Besser, P J Traine. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clinical endocrinology. vol 56. issue 3. 2002-05-09. PMID:11940041. |
the purpose of this study was to investigate the effect of serum igf-i normalization on serum lipoproteins and insulin, in patients with acromegaly receiving the gh receptor antagonist pegvisomant. |
2002-05-09 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Jan W A Smit, Hans van Dulken, Ferdinand Roelfsem. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. Clinical endocrinology. vol 56. issue 3. 2002-05-09. PMID:11940042. |
to assess the predictive value of postoperative thyrotrophin releasing hormone (trh)-induced gh responsiveness in relation to (late) postoperative outcome in patients in remission after surgery for acromegaly. |
2002-05-09 |
2023-08-12 |
Not clear |
| Scott G Thomas, Linda J Woodhouse, Sonia M Pagura, Shereen Ezza. Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. Clinical endocrinology. vol 56. issue 3. 2002-05-09. PMID:11940047. |
fatigue is a prominent symptom among patients with gh excess and acromegaly. |
2002-05-09 |
2023-08-12 |
Not clear |
| H J Kim, S H Kwon, S W Kim, D J Park, C S Shin, K S Park, S Y Kim, B Y Cho, H K Le. Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults. Hormone research. vol 56. issue 3-4. 2002-04-30. PMID:11847474. |
to investigate the diagnostic value of serum insulin-like growth factor-i (igf-i) and insulin-like growth factor-binding protein-3 (igfbp-3) measurements in adult patients with acromegaly and gh deficiency (ghd). |
2002-04-30 |
2023-08-12 |
Not clear |
| P M Stewart, A A Toogood, J W Tomlinso. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Hormone research. vol 56 Suppl 1. 2002-04-29. PMID:11786677. |
patients with acromegaly show a reduction in hepatic-derived metabolites of cortisol/cortisone - levels return to normal when gh concentrations are normalized. |
2002-04-29 |
2023-08-12 |
Not clear |
| Gemma Sesmilo, Wesley P Fairfield, Laurence Katznelson, Karen Pulaski, Pamela U Freda, Vivien Bonert, Eleni Dimaraki, Stavros Stavrou, Mary Lee Vance, Douglas Hayden, Anne Klibansk. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. The Journal of clinical endocrinology and metabolism. vol 87. issue 4. 2002-04-25. PMID:11932303. |
cardiovascular risk factors in acromegaly before and after normalization of serum igf-i levels with the gh antagonist pegvisomant. |
2002-04-25 |
2023-08-12 |
Not clear |
| Gemma Sesmilo, Wesley P Fairfield, Laurence Katznelson, Karen Pulaski, Pamela U Freda, Vivien Bonert, Eleni Dimaraki, Stavros Stavrou, Mary Lee Vance, Douglas Hayden, Anne Klibansk. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. The Journal of clinical endocrinology and metabolism. vol 87. issue 4. 2002-04-25. PMID:11932303. |
gh replacement therapy decreases inflammatory markers of cardiovascular risk, but little is known about these markers in patients with acromegaly. |
2002-04-25 |
2023-08-12 |
Not clear |
| Gemma Sesmilo, Wesley P Fairfield, Laurence Katznelson, Karen Pulaski, Pamela U Freda, Vivien Bonert, Eleni Dimaraki, Stavros Stavrou, Mary Lee Vance, Douglas Hayden, Anne Klibansk. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. The Journal of clinical endocrinology and metabolism. vol 87. issue 4. 2002-04-25. PMID:11932303. |
we investigated the effects of gh receptor blockade on inflammatory and other cardiovascular risk markers in active acromegaly. |
2002-04-25 |
2023-08-12 |
Not clear |
| M Doga, S Bonadonna, A Burattin, A Giustin. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Annals of oncology : official journal of the European Society for Medical Oncology. vol 12 Suppl 2. 2002-03-26. PMID:11762359. |
may produce excessive ghrh with subsequent gh hypersecretion and resultant acromegaly. |
2002-03-26 |
2023-08-12 |
human |
| C Parkinson, P J Traine. The place of pegvisomant in the management of acromegaly. Expert opinion on investigational drugs. vol 10. issue 9. 2002-03-15. PMID:11772281. |
conventional treatments for acromegaly include surgery, radiotherapy, dopamine agonists and somatostatin (sms) analogues, which effect disease control by lowering circulating growth hormone (gh). |
2002-03-15 |
2023-08-12 |
Not clear |
| b' S Valdemarsson, S Ljunggren, A Cervin, C Svensson, A Isaksson, C H Nordstr\\xc3\\xb6m, P Siesj\\xc3\\xb. Evaluation of surgery for acromegaly: role of intraoperative growth hormone measurement? Scandinavian journal of clinical and laboratory investigation. vol 61. issue 6. 2002-03-08. PMID:11681536.' |
intraoperative growth hormone (gh ) measurement has earlier been tried to improve surgery for acromegaly. |
2002-03-08 |
2023-08-12 |
Not clear |
| b' S Valdemarsson, S Ljunggren, A Cervin, C Svensson, A Isaksson, C H Nordstr\\xc3\\xb6m, P Siesj\\xc3\\xb. Evaluation of surgery for acromegaly: role of intraoperative growth hormone measurement? Scandinavian journal of clinical and laboratory investigation. vol 61. issue 6. 2002-03-08. PMID:11681536.' |
we calculated gh half-life after adenomectomy and evaluated the possible role of this variable in predicting the final outcome of pituitary surgery in 28 consecutive patients with acromegaly. |
2002-03-08 |
2023-08-12 |
Not clear |
| H S Kooistra, A C Okken. Secretion of prolactin and growth hormone in relation to ovarian activity in the dog. Reproduction in domestic animals = Zuchthygiene. vol 36. issue 3-4. 2002-02-28. PMID:11555356. |
acromegaly is a syndrome of tissue overgrowth and insulin resistance due to excessive growth hormone (gh) production. |
2002-02-28 |
2023-08-12 |
dog |
| H S Kooistra, A C Okken. Secretion of prolactin and growth hormone in relation to ovarian activity in the dog. Reproduction in domestic animals = Zuchthygiene. vol 36. issue 3-4. 2002-02-28. PMID:11555356. |
in contrast with the pulsatile gh secretion seen in healthy dogs, the progestagen-induced plasma gh levels in bitches with acromegaly do not have a pulsatile secretion pattern. |
2002-02-28 |
2023-08-12 |
dog |